Bristol Myers Squibb Reports First Quarter Financial Results for 2024

Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile



First Quarter Revenues were $11.9 Billion, increasing 5%


Growth Portfolio Revenues were $4.8...

Related Keywords

Puerto Rico ,United States ,Bristol Myers Squibb ,Christopher Boerner ,Pomalyst Imnovid ,Exchange Commission ,Karuna Therapeutics Inc ,European Commission ,European Union ,International Intl ,Facebook ,Mirati Therapeutics Inc ,Twitter ,Business Development ,Instagram ,B Drug Pricing Program ,European Medicines Agency ,Linkedin ,Youtube ,Securities Exchange ,Drug Administration ,Clinical Research ,Rayzebio Inc ,Bristol Myers ,Earnings Per Share ,Licensing Income Net Impact ,Karuna Therapeutics ,Myers Squibb ,Mirati Therapeutics ,Ended March ,Legacy Portfolio ,New Drug Application ,Priority Review ,Prescription Drug User Fee Act ,Biologics Application ,Blinded Independent Central Review ,Enhancing Productivity ,Statement Regarding Forward Looking ,Accepted Accounting Principles ,Nimbus Therapeutics ,Securities Act ,Securities Exchange Act ,Drug Pricing Program ,Annual Report ,Quarterly Reports ,Current Reports ,Months Ended March ,Earnings Before Income Taxes ,Income Taxes ,Earnings Attributable ,Average Common Shares Outstanding ,Common Share ,Specified Items ,Markets ,